Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, Prelude Therapeutics Inc (NASDAQ: PRLD) closed at $1.4 down -16.17% from its previous closing price of $1.67. In other words, the price has decreased by -$16.17 from its previous closing price. On the day, 0.57 million shares were traded. PRLD stock price reached its highest trading level at $1.66 during the session, while it also had its lowest trading level at $1.4.
Ratios:
For a deeper understanding of Prelude Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.21 and its Current Ratio is at 3.21. In the meantime, Its Debt-to-Equity ratio is 0.30 whereas as Long-Term Debt/Eq ratio is at 0.26.
On June 20, 2024, Barclays Downgraded its rating to Underweight which previously was Equal Weight but kept the price unchanged to $3.
On March 13, 2024, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $7.JMP Securities initiated its Mkt Outperform rating on March 13, 2024, with a $7 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 25 ’25 when Combs Andrew bought 100,000 shares for $0.69 per share. The transaction valued at 69,250 led to the insider holds 480,123 shares of the business.
Vaddi Krishna bought 675,000 shares of PRLD for $467,438 on Mar 25 ’25. The CEO now owns 1,999,296 shares after completing the transaction at $0.69 per share. On Mar 21 ’25, another insider, Vaddi Krishna, who serves as the CEO of the company, bought 15,000 shares for $0.73 each. As a result, the insider paid 10,959 and bolstered with 1,324,296 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRLD now has a Market Capitalization of 88011376 and an Enterprise Value of 78253440. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.10 while its Price-to-Book (P/B) ratio in mrq is 1.35. Its current Enterprise Value per Revenue stands at 7.453 whereas that against EBITDA is -0.656.
Stock Price History:
The Beta on a monthly basis for PRLD is 1.01, which has changed by 0.70408165 over the last 52 weeks, in comparison to a change of 0.09654534 over the same period for the S&P500. Over the past 52 weeks, PRLD has reached a high of $4.22, while it has fallen to a 52-week low of $0.61. The 50-Day Moving Average of the stock is -3.87%, while the 200-Day Moving Average is calculated to be 36.47%.
Shares Statistics:
For the past three months, PRLD has traded an average of 1.31M shares per day and 557760 over the past ten days. A total of 43.75M shares are outstanding, with a floating share count of 29.84M. Insiders hold about 60.59% of the company’s shares, while institutions hold 21.51% stake in the company. Shares short for PRLD as of 1761868800 were 567052 with a Short Ratio of 0.43, compared to 1759190400 on 601130. Therefore, it implies a Short% of Shares Outstanding of 567052 and a Short% of Float of 7.539999999999999.
Earnings Estimates
Prelude Therapeutics Inc (PRLD) is currently under the scrutiny of 1.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.28, with high estimates of -$0.26 and low estimates of -$0.3.
Analysts are recommending an EPS of between -$1.27 and -$1.27 for the fiscal current year, implying an average EPS of -$1.27. EPS for the following year is -$1.14, with 2.0 analysts recommending between -$1.05 and -$1.24.
Revenue Estimates
A total of 2 analysts believe the company’s revenue will be $20.5M this quarter.It ranges from a high estimate of $35M to a low estimate of $6M. As of. The current estimate, Prelude Therapeutics Inc’s year-ago sales were $4M
